|
Patent landscape, scope, and claims: |
United States Patent 8,822,490: Scope and Claim Strategy for Packaged, Tungsten-Free Liquid Drug Products with Controlled Formula II Impurities (Subcutaneous, Opioid-Induced Constipation)
US Drug Patent 8,822,490 is a composition-of-matter and method patent focused on a packaged liquid formulation of a compound of formula III-1 (delivered at 8 mg/0.4 mL or 12 mg/0.6 mL water) with tight residual impurity/related substance controls for a compound of formula II-1 (core threshold: <190 ppm, with dependent “fallback” limits <187, 185, 150, 125, 100, 25 ppm) and a second axis of residual tungsten exclusion (substantially free of tungsten; method embodiments recite <50 ppb and <12 ppb tungsten). The patent also ties the controlled composition to subcutaneous administration and a therapeutic context including opioid-induced constipation. The largest practical exclusivity value is expected to attach to commercial product-specific packaging and unit-dose parameters (syringe/vial/sachet/ampoule, injection volume, mg strength), not to the core active structure alone, because formula definitions appear to be doing the “structural work” while the claim spine is driven by impurity ppm limits and tungsten control.
What patents protect packaged, tungsten-free liquid compositions with impurity limits like “Formula II-1 <190 ppm” in 8,822,490?
8,822,490 protects a packaged composition comprising:
- A liquid composition containing a compound of formula III-1
- A residual level of a compound of formula II-1 below a defined ppm threshold
- The packaged composition is substantially free of tungsten
- Delivery as a unit dosage in common medical containers (syringe, vial, sachet, ampoule)
- Optionally includes specific excipients (sodium chloride, edetate calcium disodium, glycine hydrochloride) and specific unit-dose weight/volume combinations
Claim architecture that drives infringement risk
Independent claim 1 (and related composition claims 4, 7, 9, and further dependent claim sets 17–61) uses the same three gating limitations:
-
Active/formula component
- “liquid composition comprising a compound of formula III” (or III-1)
-
Impurity/related substance control
- “less than about 190 ppm of a compound of formula II” (or II-1)
- with extensive “ladder” dependent claims at 187, 185, 150, 125, 100, 25 ppm
- and an even broader “total” variant when combined with formula IV/IV-1
(“less than about 190 ppm total of formula II and formula IV”)
-
Tungsten exclusion
- “packaged composition is substantially free of tungsten”
- method claim includes explicit numeric tungsten limits: <50 ppb and <12 ppb
The consequence is a claim strategy that can be read as:
- Composition is infringed if a competitor’s finished packaged product meets both the impurity ppm limit and the tungsten exclusion.
- The “ladder” dependent claims offer multiple ways to capture off-target formulations across manufacturing processes.
What does the claim set imply about the formulation’s legal “scope”?
From the claim language alone, the scope is constrained to:
- Liquid unit doses (not lyophilized)
- Subcutaneous injectables in packaged formats
- Strong emphasis on residual impurity levels rather than structural modification of the active
- A defined “tungsten” impurity/control concept, likely linked to manufacturing equipment, catalysts, or filtration media
Because the claims recite packaged composition and include syringe/vial/sachet/ampoule, the infringement analysis is expected to focus on the commercial drug product as released rather than intermediate API or bulk.
How broadly does 8,822,490 read: composition vs method claims, and what each covers?
Composition claims (1–10, and many dependents) are aimed at the product:
- Packaged liquid containing compound III-1
- Formula II-1 below thresholds (standalone or “total” with formula IV-1)
- Tungsten substantially absent
Method claim 11 is aimed at use:
- Step (i): providing the packaged tungsten-free composition
- Step (ii): administering to a subject via subcutaneous injection
- Additional dependent method claims specify:
- therapeutic indication: opioid induced constipation (claim 13)
- tungsten numeric limits: <50 ppb (claim 14) and <12 ppb (claim 15)
- excipient presence (claim 16)
Practical split in enforcement leverage
- Product/composition claims are often easier for enforcement because they target the finished product specs (impurity ppm, tungsten ppb).
- Method/use claims can support additional leverage where the product meets the compositional limitations and is used for a covered indication.
Which formulation parameters are explicitly claimed: mg/volume, excipients, and container types?
8,822,490 includes explicit product format parameters that tighten scope:
Unit-dose strength and volume (explicit)
- 8 mg compound of formula III-1 in 0.4 mL water (claim 7)
- 12 mg compound of formula III-1 in 0.6 mL water (claims 9–10)
Tungsten and impurity thresholds (numeric ladders)
Core thresholds and fallbacks:
- Formula II-1: <190 ppm (claims 4, 7, 11)
- Formula II-1: dependent fallbacks at <187, 185, 150, 125, 100, 25 ppm (claims 18, 20, 22, 27–31, 37–41, 47–51)
- Total of Formula II and Formula IV:
- <190 ppm total (claim 2, 6)
- fallbacks at <187, 185, 150, 125, 100, 25 ppm total (claims 19, 21, 32–36, 42–46)
Container/packaging formats
Packaged composition is claimed in:
- syringe
- vial
- sachet
- ampoule
(Claims 3, 5, 12; also product claim 25/26 and method claim 26 specify syringe)
Explicit excipient set (one concrete formulation embodiment)
For the 8 mg / 0.4 mL unit dose:
- sodium chloride 2.6 mg
- edetate calcium disodium 0.16 mg
- glycine hydrochloride 0.12 mg
(claim 8)
For the 12 mg / 0.6 mL unit dose:
- sodium chloride 3.9 mg
- edetate calcium disodium 0.24 mg
- glycine hydrochloride 0.18 mg
(claim 10)
This creates at least one concrete “anchor formulation” within the patent family’s claim set.
What is the significance of “substantially free of tungsten” and how do ppb limits create hard boundaries?
8,822,490 introduces a tungsten control concept in two tiers:
-
Composition-level qualitative limitation
- “substantially free of tungsten” (claim 1; also claim 17 for certain dependent group)
-
Method-level quantitative limitations
- tungsten <50 parts per billion (claim 14)
- tungsten <12 parts per billion (claim 15)
Claim-driven inference for manufacturing specs
From an enforcement standpoint, the tungsten limitation can be operationalized as:
- If “substantially free” is interpreted broadly, then the numeric method dependents likely represent concrete target specs tied to compliant manufacture.
- If “substantially free” is interpreted narrowly, then tungsten ppb tests (and test method, sampling, and stability) become the key technical battleground.
How does 8,822,490 handle impurity “Formula II-1” and impurity “Formula IV-1” via “total” limits?
The claim set includes both:
- standalone impurity limits for compound of formula II-1
- combined “total” limits for formula II-1 plus formula IV-1
Standalone control
- “less than about X ppm of a compound of formula II-1”
(Claims 4, 7, 18, 20, 22, 24, 27–31, 37–41, 47–51, 57–61)
Total control
- “less than about X ppm total of compound of formula II-1 and compound of formula IV-1”
(claim 6 plus dependents 19, 21, 32–36, 42–46)
Why “total” matters commercially
A competitor can sometimes engineer around a single-spec limit (e.g., reduce one impurity) but still fail due to:
- shifting impurities between II-1 and IV-1
- or introducing a different degradation pathway that increases the “total” metric
The “total” ladder claims increase the likelihood that a manufacturing change aimed at one impurity will not fully avoid the patent.
What therapeutic scope is claimed: is opioid-induced constipation the only indication?
The method claim 11 is framed as:
- administering the unit dosage via subcutaneous injection to a subject
Dependent claim 13 adds:
- “subject is suffering from opioid induced constipation”
So, opioid-induced constipation is a dependent use limitation. The independent method claim scope still covers subcutaneous administration of the tungsten-free, impurity-controlled unit dose even if the dependent indication is not met. In practice, infringement depends on evidence of:
- the product composition and unit dosage specs, and
- the administration route,
with indication evidence required only for the dependent claim.
How strong is the patent estate logic in 8,822,490: are these claims likely to be narrow or broadly enforceable?
Based only on claim text, 8,822,490 is likely narrow in structural scope and broad in spec-based scope:
- Narrow in that it depends on the specific “formula III-1 / formula II-1 / formula IV-1” identity
- Broad in that it does not rely on clinical effect differences, and instead uses measurable ppm/ppb thresholds and packaging/unit-dose formats
Key enforceability levers
- Finished product testing: ppm tungsten and impurity specs can be tested from the commercial product
- Unit dose format: syringe/vial/sachet/ampoule and the injection presentation reduce easy “design-around” via delivery device switching
- Multiple fallback thresholds: the ladder of dependent claims reduces the probability that a competitor’s formulation lands in a “safe” window
Likely design-around vectors (within this patent’s text constraints)
A competitor would need to ensure at least one of these major limitations is not met:
- impurity II-1 above threshold
- impurity II-1 plus IV-1 total above threshold (if aiming to avoid total-limit dependent claims)
- tungsten above “substantially free” interpretation or above numeric ppb limits for method embodiments
- avoid the claimed unit-dose strengths/volumes or packaging formats, though claim 1/4/11 appear to cover multiple strengths through formula III-1 units with specific mg/volume only in dependents
What are the key expiration and exclusivity timing questions for 8,822,490?
No patent filing date, grant date, priority date, or PTA/adjustment data was provided in the record. Without those, the exclusivity and expiration timeline cannot be computed accurately from claim text alone.
What generic entry risks exist if a competitor makes a tungsten-free subcutaneous injectable but changes impurity profile?
8,822,490 creates a risk profile driven by:
- ability to control formula II-1 below multiple ppm thresholds
- ability to keep tungsten below “substantially free” and in method dependents under <50 ppb or <12 ppb
- ability to keep combined impurity (II-1 + IV-1) below the “total” thresholds
A generic or biosimilar-type entrant is not just competing on active equivalence. It must match (or better) the release specification on impurity identity/level and tungsten.
What patent litigation challenges could look like for 8,822,490?
Given the claim set, the most probable litigation themes are:
- Whether the competitor’s product meets ppm limits for the specific impurity identity tied to “formula II-1” (and combined “total” with “formula IV-1”)
- Whether the competitor’s product is “substantially free of tungsten” and, for method dependents, whether tungsten is actually <50 ppb or <12 ppb
- Whether the accused product is a “packaged composition” in one of the recited container types and is administered via subcutaneous injection
- Whether excipients (edetate calcium disodium, glycine hydrochloride) are required only for dependents (claims 8/10 and 16), not for the core independent claims
How do these claims compare with typical subcutaneous injectable impurity-tungsten patents?
Relative to general formulation patents, 8,822,490’s distinguishing features are:
- Hard ppm thresholds for a defined impurity (formula II-1) and a “total” impurity metric (II-1 + IV-1)
- Explicit tungsten control, including ppb values in method dependents
- Claiming the packaged unit dose and commonly used delivery containers
- Including unit-dose strength and volume anchors for at least one embodied formulation (8 mg/0.4 mL and 12 mg/0.6 mL)
That combination is designed to convert manufacturing quality controls into enforceable IP boundaries.
Key claim-by-claim scope map (high-signal features)
| Claim group |
Core limitation(s) |
Key thresholds / parameters |
| Claim 1 (composition) |
Packaged liquid with compound III; substantially tungsten-free; impurity II below threshold |
Formula II <190 ppm; tungsten substantially free |
| Claims 2 & 6 (composition dependents) |
Add “total” impurity II + IV |
Total <190 ppm (and dependents down to 25 ppm) |
| Claims 3/5/12 & packaging |
Packaging types |
syringe / vial / sachet / ampoule |
| Claims 7–10 (anchored unit-dose examples) |
Strength and volume + impurity spec; excipients in one embodiment |
8 mg/0.4 mL; 12 mg/0.6 mL; NaCl, edetate Ca disodium, glycine HCl |
| Claim 11 (method) |
Provide unit dose composition; administer subcutaneously |
via subcutaneous injection |
| Claims 13 (method dependent) |
Indication |
opioid induced constipation |
| Claims 14–15 (method dependent) |
Numeric tungsten limits |
tungsten <50 ppb and <12 ppb |
| Claims 17–61 (ladder dependents) |
Tighten impurity ppm and total-impurity ppm |
fallbacks: <187, 185, 150, 125, 100, 25 ppm |
Key Takeaways
- 8,822,490 is spec-driven IP: exclusivity hinges on meeting defined impurity levels (formula II-1 and optionally II-1 + IV-1 total) and tungsten exclusion in the finished packaged product.
- The claim set includes multiple “fallback” impurity thresholds down to 25 ppm, reducing the chance of design-around via minor spec changes.
- Tungsten control is enforceably quantified in method dependents (<50 ppb and <12 ppb), making tungsten testing a litigation focal point.
- Commercial product form matters: the patent claims packaged formats (syringe/vial/sachet/ampoule) and includes unit-dose strength/volume examples with defined excipient composition.
- Indication scope: opioid-induced constipation is a dependent method claim; independent method coverage centers on subcutaneous administration of the specific tungsten-free, impurity-controlled unit dose.
FAQs
-
Does 8,822,490 require the competitor to match excipients like sodium chloride, edetate calcium disodium, and glycine hydrochloride?
No excipient set is required for the independent composition and method claims as provided; the excipient quantities appear in dependent embodiment claims.
-
Can a generic avoid infringement by only adjusting formula II-1 while ignoring formula IV-1?
Avoiding standalone II-1 limits may still fail “total” II-1 + IV-1 dependent claims if the competitor increases formula IV-1.
-
What is the highest-risk parameter for product testing under 8,822,490?
The impurity spec tied to “formula II-1” and the tungsten level in the finished packaged unit, given the numeric ppm/ppb ladders.
-
Is the method claim limited to opioid-induced constipation?
Opioid-induced constipation is a dependent limitation (claim 13). The base method claim 11 is framed around subcutaneous administration of the claimed unit dosage composition.
-
Does delivery device (syringe vs vial) affect infringement?
The patent expressly claims multiple packaging types. A switch in container alone may not avoid infringement if the packaged product still meets all other claim limitations.
References
- United States Patent US 8,822,490 (claims provided in user prompt).
More… ↓
⤷ Start Trial
|
